Table 4 Analyses regarding the prognostic factors for overall survival.
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
CONUT | 1.514 (1.108–2.198) | 0.013 | 1.220 (1.023–1.455) | 0.027 |
CONUT ≤ 2 | ||||
CONUT ≥ 3 | ||||
Patient age | 0.669 (0.472–0.947) | 0.023 | 0.673 (0.460–0.985) | 0.042 |
≤40 | ||||
>40 | ||||
ER | 1.346 (0.906–1.999) | 0.141 | ||
− | ||||
+ | ||||
PR | 0. 684 (0.490–0.956) | 0.026 | 0.721 (0.502–1.034) | 0.076 |
− | ||||
+ | ||||
HER2 | 0.879 (0.605–1.279) | 0.501 | ||
+ | ||||
− | ||||
Ki-67 status | 1.161 (0.811–1.662) | 0.415 | ||
+ | ||||
− | ||||
pT Stage | 1.452 (1.257–1.678) | <0.001 | 1.219 (1.017–1.462) | 0.031 |
1 | ||||
2 | ||||
3 | ||||
4 | ||||
pN Stage | 1.582 (1.338–1.870) | <0.001 | 1.401 (1.135–1.730) | 0.002 |
0 | ||||
1 | ||||
2 | ||||
3 | ||||
Molecular subtype | 0.901 (0.854–1.076) | 0.250 | ||
Luminal A | ||||
Luminal B | ||||
HER2-enriched | ||||
TNBC | ||||
Histological grade | 1.683 (1.274–1.792) | <0.001 | 1.635 (1.193–2.381) | 0.003 |
I-II | ||||
III | ||||
Surgery type | 1.077 (0.821–1.46) | 0.62 | ||
Mastectomy | ||||
BCS | ||||
Chemotherapy | 0.932 (0.721–1.236) | 0.718 | ||
Yes | ||||
No | ||||
Hormone therapy | 0.905 (0.678–1.205) | 0.462 | ||
Yes | ||||
No | ||||
Radiotherapy | 1.036 (0.774–1.387) | 0.812 | ||
Yes | ||||
No | ||||
Target therapy | 1.119 (0.836–1.498) | 0.45 | ||
Yes | ||||
No | ||||